PMID- 15207359
OWN - NLM
STAT- MEDLINE
DCOM- 20040824
LR  - 20191210
IS  - 0306-4522 (Print)
IS  - 0306-4522 (Linking)
VI  - 126
IP  - 2
DP  - 2004
TI  - Role of the calcium/calmodulin-dependent protein kinase ii (CaMKII) in the 
      morphine-induced pharmacological effects in the mouse.
PG  - 415-21
AB  - Calcium/calmodulin-dependent protein kinase II (CaMKII) is a family of 
      multifunctional protein kinases that activates signaling pathways. The present 
      study was designed to ascertain whether CaMKII could play a substantial role in 
      the expression of morphine-induced antinociception, hyperlocomotion and rewarding 
      effect in the mouse. An i.c.v. pretreatment with a CaMKII inhibitor KN-93 failed 
      to affect the antinociception and hyperlocomotion induced by s.c. administration 
      of a prototype micro-opioid receptor agonist morphine. In contrast, the 
      morphine-induced place preference was significantly attenuated by i.c.v. 
      pretreatment with KN-93. The levels of phosphorylated-CaMKII (p-CaMKII) in the 
      limbic forebrain, but not in the frontal cortex and the lower midbrain, were 
      significantly increased in morphine-conditioned mice, whereas the levels of 
      CaMKII in three brain regions obtained from morphine-conditioned mice were not 
      changed. This up-regulation of p-CaMKII in the limbic forebrain obtained from 
      morphine-conditioned mice was significantly inhibited by i.c.v. pretreatment with 
      KN-93. These results provide evidence that the increase in CaMKII activity in the 
      mouse limbic forebrain may contribute to the rewarding effect, but not the 
      antinociception and the hyperlocomotion, induced by morphine.
CI  - Copyright 2004 IBRO
FAU - Narita, M
AU  - Narita M
AD  - Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical 
      Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan. narita@hoshi.ac.jp
FAU - Matsumura, Y
AU  - Matsumura Y
FAU - Ozaki, S
AU  - Ozaki S
FAU - Ise, Y
AU  - Ise Y
FAU - Yajima, Y
AU  - Yajima Y
FAU - Suzuki, T
AU  - Suzuki T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Benzylamines)
RN  - 0 (Sulfonamides)
RN  - 139298-40-1 (KN 93)
RN  - 76I7G6D29C (Morphine)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinase Type 2)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
SB  - IM
MH  - Animals
MH  - Benzylamines/pharmacology
MH  - Calcium-Calmodulin-Dependent Protein Kinase Type 2
MH  - Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors/*physiology
MH  - Conditioning, Psychological/drug effects/*physiology
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Morphine/*pharmacology
MH  - Motor Activity/drug effects/*physiology
MH  - Pain Measurement/drug effects/methods
MH  - Prosencephalon/drug effects/*enzymology
MH  - Sulfonamides/pharmacology
EDAT- 2004/06/23 05:00
MHDA- 2004/08/25 05:00
CRDT- 2004/06/23 05:00
PHST- 2004/03/06 00:00 [accepted]
PHST- 2004/06/23 05:00 [pubmed]
PHST- 2004/08/25 05:00 [medline]
PHST- 2004/06/23 05:00 [entrez]
AID - S0306452204001824 [pii]
AID - 10.1016/j.neuroscience.2004.03.006 [doi]
PST - ppublish
SO  - Neuroscience. 2004;126(2):415-21. doi: 10.1016/j.neuroscience.2004.03.006.